Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAWNA-FES: Dalpiciclib Post-CDK4/6i Failure in HR+/HER2- MBC
NCT05861830Phase 3Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- May 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of dalpiciclib in breast cancer, sponsored by Peking Union Medical College Hospital. Started May 2023; status: recruiting.
02
Drugs
dalpiciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05861830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05861830.